HIKAL
|
HIKAL Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 5.64 | 6.36 | 13.02 | 10.80 | 6.85 |
CEPS(Rs) | 15.18 | 15.20 | 20.78 | 17.71 | 13.54 |
DPS(Rs) | 1.20 | 1.20 | 1.60 | 2.00 | 1.20 |
Book NAV/Share(Rs) | 96.32 | 91.93 | 86.62 | 75.70 | 66.22 |
Tax Rate(%) | 27.12 | 25.61 | 26.56 | 35.50 | 33.29 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 14.96 | 12.71 | 17.53 | 18.77 | 18.12 |
EBIT Margin(%) | 8.51 | 7.59 | 12.86 | 14.10 | 11.88 |
Pre Tax Margin(%) | 5.35 | 5.21 | 11.25 | 12.00 | 8.40 |
PAT Margin (%) | 3.90 | 3.87 | 8.26 | 7.74 | 5.60 |
Cash Profit Margin (%) | 10.49 | 9.26 | 13.19 | 12.69 | 11.07 |
Performance Ratios | |||||
ROA(%) | 2.86 | 3.33 | 7.39 | 6.84 | 4.62 |
ROE(%) | 6.00 | 7.12 | 16.04 | 15.22 | 10.74 |
ROCE(%) | 7.82 | 8.47 | 15.21 | 16.15 | 12.44 |
Asset Turnover(x) | 0.73 | 0.86 | 0.89 | 0.88 | 0.82 |
Sales/Fixed Asset(x) | 1.06 | 1.37 | 1.54 | 1.57 | 1.49 |
Working Capital/Sales(x) | 8.50 | 7.29 | 9.96 | 7.76 | 8.45 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.94 | 0.73 | 0.65 | 0.64 | 0.67 |
Receivable days | 101.46 | 79.34 | 86.73 | 87.62 | 83.56 |
Inventory Days | 63.45 | 58.25 | 55.96 | 61.44 | 81.93 |
Payable days | 131.04 | 92.70 | 87.68 | 86.55 | 84.90 |
Valuation Parameters | |||||
PER(x) | 46.91 | 44.34 | 30.92 | 13.29 | 10.22 |
PCE(x) | 17.44 | 18.55 | 19.37 | 8.10 | 5.17 |
Price/Book(x) | 2.75 | 3.07 | 4.65 | 1.90 | 1.06 |
Yield(%) | 0.45 | 0.43 | 0.40 | 1.39 | 1.71 |
EV/Net Sales(x) | 2.27 | 2.06 | 2.88 | 1.36 | 0.96 |
EV/Core EBITDA(x) | 15.06 | 15.87 | 16.17 | 7.14 | 5.22 |
EV/EBIT(x) | 26.73 | 27.13 | 22.37 | 9.65 | 8.07 |
EV/CE(x) | 2.03 | 2.21 | 3.21 | 1.52 | 0.99 |
M Cap / Sales | 1.83 | 1.72 | 2.55 | 1.03 | 0.57 |
Growth Ratio | |||||
Net Sales Growth(%) | -11.79 | 4.13 | 12.92 | 14.14 | -5.18 |
Core EBITDA Growth(%) | 2.67 | -24.02 | 5.36 | 18.42 | -7.83 |
EBIT Growth(%) | -1.04 | -38.56 | 2.95 | 35.55 | -13.74 |
PAT Growth(%) | -11.20 | -51.16 | 20.55 | 57.68 | -18.08 |
EPS Growth(%) | -11.20 | -51.16 | 20.55 | 57.68 | -18.08 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.69 | 0.66 | 0.63 | 0.65 | 0.79 |
Current Ratio(x) | 1.28 | 1.42 | 1.24 | 1.32 | 1.27 |
Quick Ratio(x) | 0.88 | 0.94 | 0.84 | 0.94 | 0.79 |
Interest Cover(x) | 2.69 | 3.19 | 8.00 | 6.70 | 3.41 |
Total Debt/Mcap(x) | 0.25 | 0.22 | 0.14 | 0.34 | 0.75 |
Compare Financial Ratios of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹5,486.9 Cr | 15.3% | 17% | 61% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹431,544.0 Cr | 2.8% | -2.7% | 50.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹164,865.0 Cr | 3.5% | 5.4% | 67.6% | Stock Analytics | |
CIPLA | ₹123,920.0 Cr | 2.9% | -1.2% | 25.5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹102,224.0 Cr | 2.1% | -3.9% | 6.9% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹98,832.3 Cr | 3.3% | -2% | 53.5% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | 15.3% |
17% |
61% |
SENSEX | 1.1% |
1.1% |
22.2% |
You may also like the below Video Courses